Unveiling Groundbreaking Advances
PHILADELPHIA, Oct. 4, 2024 /PRNewswire/ — Carisma Therapeutics Inc. (NASDAQ: CARM) (“Carisma”), a pioneering force in the field of immunotherapy, has sent ripples of anticipation through the medical community as it prepares to showcase its groundbreaking research at the esteemed Society for Immunotherapy of Cancer (SITC) conference in Houston, Texas, from November 6 – 10, 2024.
Forward-Thinking Initiatives to Be Revealed
Details on the poster presentations at SITC 2024 are below:
Title: Witness the remarkable pre-clinical efficacy of a revolutionary anti-GPC3 in vivo CAR-M for hepatocellular carcinoma. Discover more in Publication Number 329 on Friday, Nov. 8, 2024, at Exhibit Halls A B George R. Brown Convention Center.
Title: Embark on a Phase 1 journey with an intriguing First-in-Human study of autologous monocytes engineered to carry an anti-HER2 chimeric antigen receptor (CAR) for participants with HER2 overexpressing solid tumors. Dive into Publication Number 659 on Friday, Nov. 8, 2024, at Exhibit Halls A B George R. Brown Convention Center.
Accessibility and Visibility
For those unable to attend the conference in person, the posters presented at SITC 2024 will be available online in the “Publications” section of Carisma’s website following the commencement of the poster session.
Insight into Carisma Therapeutics
Carisma Therapeutics Inc. stands at the vanguard of medical innovation. With its headquarters nestled in the bustling city of Philadelphia, PA, Carisma is dedicated to harnessing the power of its proprietary cell engineering platform to craft transformative immunotherapies targeting cancer and other critical ailments. By focusing on engineered macrophages and monocytes, key players in the immune response orchestra, Carisma embarks on a quest to redefine the boundaries of medical possibilities.
A Glimpse into the Future
Cautionary Note on Forward-Looking Statements
Journeying into the future of medical science is an endeavor fraught with challenges and uncertainties. While Carisma’s vision is one of promise and potential, it is crucial to recognize that the road ahead is paved with risks. From regulatory hurdles to financial constraints, the path to medical breakthroughs is laden with obstacles that demand tenacity and resilience.
A Deeper Look into Carisma Therapeutics Inc.
Carisma Therapeutics Inc., a pioneer in the field of developing innovative immunotherapies, is gearing up to make waves with its upcoming presentations at the SITC 2024. Let’s delve into the exciting developments and what investors can anticipate from this forward-thinking company.
Examining Risk Factors and Forward-Looking Statements
As with any investment opportunity, it is important to consider the risks and uncertainties associated with Carisma Therapeutics Inc. These factors, outlined in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, play a crucial role in understanding the potential variations in Carisma’s actual results from the forward-looking statements.
Commitment to Transparency and Compliance
Carisma stands firm in its dedication to transparency and compliance with regulatory standards. The Company’s continuous efforts to address risks, uncertainties, and other essential factors are evident in its recent filings with the Securities and Exchange Commission. This commitment ensures that investors are well-informed and equipped to make informed decisions.
Engaging with Stakeholders
For investors seeking additional information or clarity, Shveta Dighe, the Head of Investor Relations at Carisma Therapeutics, serves as a valuable point of contact. Reach out to her via the provided email at investors@carismatx.com to engage directly with the company and gain insights into the investment landscape.
Media Relations and Contact Information
For media inquiries or press-related matters, Julia Stern, a key contact at Carisma Therapeutics, is available for assistance. Get in touch with her at (763) 350-5223 or through email at jstern@realchemistry.com to explore media collaborations and information dissemination opportunities.
Exploring the Future with Carisma Therapeutics Inc.
Carisma Therapeutics Inc.’s presence at the SITC 2024 signifies a significant step forward in the realm of cutting-edge biotechnology. The company’s proactive approach to showcasing its advancements demonstrates a commitment to innovation and industry leadership. Investors and industry enthusiasts are poised to witness firsthand the transformative potential of Carisma’s pioneering initiatives.
View original content to download multimedia:
Visit Here for More Information
SOURCE Carisma Therapeutics Inc.
© 2024 Benzinga.com. Benzinga refrains from dispensing investment advice. All rights reserved.